Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLY R AMANN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1134116783
CMS profile
187578
Location
ROY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$468.94

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $468.94 28

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLY R AMANN

NPI 1134116783 · CMS profile ID 187578

Allopathic & Osteopathic Physicians / Family Medicine

ROY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134116783?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLY R AMANN, NPI 1134116783, CMS profile ID 187578. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134116783?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KELLY R AMANN, NPI 1134116783, CMS profile ID 187578. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134116783?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KELLY R AMANN, NPI 1134116783, CMS profile ID 187578, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134116783?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $468.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $17.1112/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241247888 CMS
Astellas Pharma US Inc $16.1712/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238582712 CMS
GlaxoSmithKline, LLC. $20.4211/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191583500 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.5111/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241247886 CMS
Axsome Therapeutics, Inc. $20.6411/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235586227 CMS
Astellas Pharma US Inc $18.6610/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238571901 CMS
AstraZeneca Pharmaceuticals LP $13.9310/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206172512 CMS
Dynavax Technologies Corporation $12.0910/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182974067 CMS
GlaxoSmithKline, LLC. $13.9909/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190666019 CMS
Amgen Inc. $15.4309/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228677371 CMS
Astellas Pharma US Inc $20.9108/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238648591 CMS
ABBVIE INC. $21.7008/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201408541 CMS
GlaxoSmithKline, LLC. $15.1207/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190998621 CMS
Abbott Laboratories $23.6807/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241023689 CMS
GlaxoSmithKline, LLC. $15.9107/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191397125 CMS
Janssen Pharmaceuticals, Inc $14.4006/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174992756 CMS
Lilly USA, LLC $16.0005/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186725049 CMS
Phathom Pharmaceuticals, Inc. $12.0305/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219307343 CMS
GlaxoSmithKline, LLC. $15.8505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190645951 CMS
Lilly USA, LLC $13.5204/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186740737 CMS
Exact Sciences Corporation $13.5504/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235265008 CMS
Biogen, Inc. $15.9204/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208459462 CMS
Organon LLC $8.4003/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237658374 CMS
Janssen Pharmaceuticals, Inc $14.8102/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174992600 CMS
SANOFI-AVENTIS U.S. LLC $21.6502/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233336903 CMS
GlaxoSmithKline, LLC. $17.5402/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191339376 CMS
PFIZER INC. $23.5101/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231111349 CMS
Lilly USA, LLC $15.4901/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186658083 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $481.24 35
PY2020 $352.65 23
PY2021 $704.02 48
PY2022 $510.64 34
PY2023 $475.66 30
PY2024 $710.07 47
PY2025 $468.94 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $267,494.93 21
PY2024 Principal investigator $509,633.49 63
PY2023 Principal investigator $838,851.01 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $575.00 12/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC DBA AVACARE
IS354CS6 No dispute reported 06/30/2026 1246792124
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,077.00 11/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549991
Principal investigator 1 Genentech, Inc. $3,800.00 11/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211640188
Principal investigator 1 AstraZeneca Pharmaceuticals LP $900.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185549989
Principal investigator 1 Exact Sciences Corporation $69.00 09/25/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening: COMPASS No dispute reported 06/30/2026 1244037431
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,667.77 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185549997
Principal investigator 1 Genentech, Inc. $900.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211639788
Principal investigator 1 Exact Sciences Corporation $4,500.00 08/29/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening: COMPASS No dispute reported 06/30/2026 1244037483
Principal investigator 1 Genentech, Inc. $2,697.00 08/22/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211640091
Principal investigator 1 Genentech, Inc. $18,536.00 08/20/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211640095
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 07/16/2025 Non-covered Recipient Entity
OGDEN CLINIC GRAND VIEW
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185549993
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,117.70 06/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185549995
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,988.20 05/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185549987
Principal investigator 1 AstraZeneca Pharmaceuticals LP $154,115.70 05/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185549985
Principal investigator 1 Genentech, Inc. $143.00 03/28/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589111
Principal investigator 1 Genentech, Inc. $162.00 02/21/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589235
Principal investigator 1 AstraZeneca Pharmaceuticals LP $745.00 02/12/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549999
Principal investigator 1 Exact Sciences Corporation $1,000.00 01/31/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
Informed Choice Intervention for Colorectal Cancer Screening: COMPASS No dispute reported 06/30/2026 1244037480
Principal investigator 1 Genentech, Inc. $750.00 01/29/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589217
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,224.56 01/22/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185549983
Principal investigator 1 Genentech, Inc. $527.00 01/22/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211589302